Laboratorio Of Terapia Cellulare Stefano Verri

Monza, Italy

Laboratorio Of Terapia Cellulare Stefano Verri

Monza, Italy
SEARCH FILTERS
Time filter
Source Type

Hrusak O.,Charles University | Ratei R.,Charité - Medical University of Berlin | Gaipa G.,Laboratorio Of Terapia Cellulare Stefano Verri | Luria D.,Schneider Childrens Medical Center | And 7 more authors.
Cytometry Part B - Clinical Cytometry | Year: 2014

Background Flow cytometry is a valuable part in the routine diagnostics of acute leukemia (AL). Although internationally recognized definitions of main AL subsets are available, there is currently no consensus format for the short summary of clinical flow cytometry reports. Since clinical reports are too long for most database purposes, there is a need for a standardized format of their short summaries. Methods The Associazione Italiana Ematologia Oncologia Pediatrica - Berlin Frankfurt Muenster (AIEOP-BFM) Flow Network that encompasses reference diagnostics laboratories in Australia, Austria, Czechia, Germany, Israel, Italy, and Switzerland have designed a pro-forma for the summary of flow cytometry results in the diagnosis of leukemia. The process involved several meetings and other communications, during which the group established a consensus on the essentials that lead to the diagnostic conclusions in childhood AL. Results The "Flow Diagnostics Essential (FDE) Code" is a result from an agreement within the AIEOP-BFM Flow Network. In a standardized format, it reports the extent of the infiltration by a malignant clone, followed by description antigen expression as strong, weak or negative, and a diagnostic conclusion. Conclusions A consensus brief format (the "FDE Code") has been designed as a brief summary of the diagnostic immunophenotype of childhood AL. It is also applicable for the diagnostic investigation of other malignancies by flow cytometry. The FDE code may be included in the final clinical report and/or used in the setting of a multicenter clinical trial database. © 2013 International Clinical Cytometry Society © 2013 Clinical Cytometry Society.


Lucchini G.,University of Milan Bicocca | Dander E.,University of Milan Bicocca | Pavan F.,University of Milan Bicocca | Di Ceglie I.,University of Milan Bicocca | And 12 more authors.
Stem Cells International | Year: 2012

Mesenchymal stromal cells (MSC) are tested in clinical trials to treat graft versus host disease (GvHD) after stem cell transplantation (SCT). In vitro studies demonstrated MSC's broad immunosuppressive activity. As infections represent a major risk after SCT, it is important to understand the role of MSC in this context. We analyzed 24 patients (pts) receiving MSC for GvHD in our Unit between 2009 and 2011. We recorded viral reactivations as measured in whole blood with polymerase chain reaction for 100 days following MSC administration. In patients with a documented viral reactivation in the first 3 days following MSCs infusion the frequency of virus-specific IFNgamma-producing cells was determined through enzyme-linked immunospot assay. In our cohort of patients viral reactivation after MSC infusion occurred in 45 of the cases, which did not significantly differ from the incidence in a historical cohort of patients affected by steroid resistant GvHD and treated with conventional immunosuppression. No patient presented severe form of infection. Two cases could be checked for immunological response to viral stimulus and demonstrated virus specific T-cytotoxic lymphocyte activity. In our experience MSC infusion did not prove to trigger more frequent or severer viral reactivations in the post transplantation setting. © Copyright 2012 Giovanna Lucchini et al.


Belingheri M.,Dialysis and Transplantation Unit | Lazzari L.,Cell Factory Franco Calori | Parazzi V.,Cell Factory Franco Calori | Groppali E.,Dialysis and Transplantation Unit | And 9 more authors.
Biologicals | Year: 2013

Focal segmental glomerulosclerosis (FSGS) is the most frequent acquired renal condition resulting in end stage kidney disease in children. We describe a cell therapy treatment with human allogeneic bone marrow mesenchymal stem cells (MSC) in a 13-year-old patient developing recurrent FSGS after renal transplantation, which was not responding to conventional therapy.This treatment relied on the following measurements:clinical and laboratory evaluation of renal function, proteome array, biopsy, short tandem repeat assay.Before MSC treatment, the patient needed weekly plasmapheresis to achieve proteinuria-to-creatininuria ratio below 5. After three MSC infusions without adverse events, the patient has a stable renal function and the proteinuria target was reached without plasmapheresis. In addition, some circulating inflammatory factors decreased and their levels were still low after one year.This is the first report of an MSC treatment in an FSGS patient. Even though different factors may have contributed to the clinical results, after MSC infusion a stable reduction in the serum level of several inflammatory factors has been registered and the patient does not need anymore plasmapheresis to keep proteinuria under control.In addition, this encouraging single case let us identify some putative efficacy biomarkers that could be of clinical interest in chronic kidney diseases. © 2013 The International Alliance for Biological Standardization.

Loading Laboratorio Of Terapia Cellulare Stefano Verri collaborators
Loading Laboratorio Of Terapia Cellulare Stefano Verri collaborators